Global Viscosupplementation Market Forecast to Grow at 9.02% CAGR from 2025 to 2033

According to a comprehensive report by Renub Research, the global viscosupplementation market is projected to reach US$10.16 billion by 2033, up from US$4.66 billion in 2024, growing at a CAGR of 9.02% during the forecast period from 2025 to 2033. This market growth is primarily fueled by the increasing prevalence of osteoarthritis, an aging global population, and a rising preference for non-surgical joint pain management options, particularly hyaluronic acid-based injections.

What is Viscosupplementation and Why It’s Booming

Viscosupplementation is a medical procedure that involves injecting hyaluronic acid (HA) into the synovial joint, most commonly the knee, to relieve pain and restore lubrication and cushioning. As a minimally invasive, outpatient treatment with relatively fewer side effects, viscosupplementation is increasingly seen as a preferred alternative to pain medications and even surgery.

The treatment is especially beneficial for patients in the early-to-moderate stages of osteoarthritis (OA) who are not yet candidates for total joint replacement. Given the global surge in osteoarthritis cases and growing awareness of such innovative interventions, demand is projected to remain robust over the next decade.

Key Drivers Fueling the Viscosupplementation Market

1. Rising Prevalence of Osteoarthritis Worldwide

Osteoarthritis affects over 500 million people globally, and its prevalence continues to grow with an aging population and lifestyle risk factors like obesity and sedentary behavior. As the most common form of arthritis, OA is a significant driver behind the increased demand for viscosupplementation procedures.

2. Preference for Non-Invasive Therapies

Many patients and healthcare providers are opting for non-surgical interventions due to shorter recovery times, reduced costs, and minimal complications. Viscosupplementation meets this demand, especially among those who seek pain relief without invasive orthopedic procedures.

3. Increasing Geriatric Population

By 2033, nearly 1 in 6 people globally will be over the age of 60, as per WHO projections. Since age is the most significant risk factor for osteoarthritis, the growing elderly population translates directly to a larger patient base for viscosupplementation.

4. Advancements in HA-Based Injectables

Technological developments in the purity, molecular weight, and bioavailability of hyaluronic acid formulations are enhancing treatment outcomes, thereby encouraging more adoption by orthopedic specialists and general practitioners.

Market Segmentation Analysis

The viscosupplementation market can be segmented by product type, application, end-user, and geography. Among these, single-injection products are gaining popularity due to patient convenience, while three-injection therapies remain dominant for their long-standing clinical effectiveness.

By Product Type:

  • Single Injection

  • Three Injection

  • Five Injection

By Application:

  • Knee Osteoarthritis

  • Hip Osteoarthritis

  • Shoulder Osteoarthritis

  • Others

By End-User:

  • Hospitals

  • Ambulatory Surgical Centers (ASCs)

  • Orthopedic Clinics

Regional Insights: North America Holds Major Share, Asia-Pacific Rising Fast

North America

North America, particularly the United States, continues to dominate the viscosupplementation market due to:

  • High healthcare spending

  • Advanced reimbursement systems

  • High osteoarthritis prevalence

  • Widespread use of innovative therapies

Europe

Europe ranks second in market share, with growing awareness and adoption in countries like Germany, France, and the UK. An aging demographic and public healthcare infrastructure are contributing factors.

Asia-Pacific

The Asia-Pacific region is the fastest-growing market, supported by:

  • Expanding medical tourism

  • Increasing disposable income

  • Growing investments in healthcare infrastructure

  • Rising awareness about minimally invasive treatments

Countries like China, Japan, South Korea, and India are witnessing rapid uptake, particularly in urban hospitals and specialty clinics.

Competitive Landscape: Innovation and Strategic Partnerships Drive Growth

Key players in the viscosupplementation market are leveraging R&D, mergers & acquisitions, and product launches to gain competitive advantage. Some of the leading companies include:

  • Sanofi S.A.

  • Zimmer Biomet Holdings Inc.

  • Seikagaku Corporation

  • Anika Therapeutics Inc.

  • Fidia Farmaceutici S.p.A.

  • Bioventus LLC

  • LG Chem

  • Chugai Pharmaceutical Co., Ltd.

These companies are actively investing in next-generation HA injectables, global market expansion, and regulatory approvals to meet growing demand and remain competitive.

Challenges and Restraints

While the market outlook remains positive, it faces some challenges:

  • Cost of treatment without reimbursement in many countries

  • Limited long-term efficacy in advanced OA cases

  • Need for repeated procedures, which may discourage some patients

  • Regulatory hurdles for new product approvals

However, ongoing research and favorable clinical outcomes continue to support the credibility and adoption of viscosupplementation therapies.

Market Outlook and Future Trends

Combination Therapies

The integration of viscosupplementation with platelet-rich plasma (PRP) or stem cell therapy is being actively explored to enhance joint healing and pain relief. These combination approaches could redefine the standard of care for OA patients.

Home-Based Treatment Models

With innovations in telehealth and at-home administration kits, viscosupplementation could become more accessible in outpatient and homecare settings, especially in remote or underserved areas.

Expanding Beyond Knee OA

Manufacturers are increasingly studying the effectiveness of HA injections in hips, shoulders, and ankles, opening new revenue streams.

10 Frequently Asked Questions (FAQs)

1. What is viscosupplementation?

Viscosupplementation is a medical procedure in which hyaluronic acid is injected into a joint, most commonly the knee, to reduce pain and improve joint movement.

2. What is the current size of the global viscosupplementation market?

As of 2024, the global viscosupplementation market is valued at US$4.66 billion, according to Renub Research.

3. What is the projected market size by 2033?

The market is expected to reach US$10.16 billion by 2033.

4. What is the forecasted CAGR for 2025 to 2033?

The market is anticipated to grow at a CAGR of 9.02% during this period.

5. Who are the key players in the market?

Leading companies include Sanofi, Zimmer Biomet, Anika Therapeutics, Bioventus, and Seikagaku Corporation.

6. Which region leads the viscosupplementation market?

North America currently holds the largest share due to high healthcare spending and early adoption of advanced treatments.

7. Why is the demand for viscosupplementation increasing?

The demand is rising due to growing osteoarthritis cases, aging population, and preference for non-invasive joint therapies.

8. What are the main product types in this market?

The main product types include single, three, and five-injection viscosupplementation systems.

9. Are there any risks associated with viscosupplementation?

Generally considered safe, minor risks include joint swelling, pain, or allergic reactions at the injection site.

10. Where can I access the full market report?

You can find the full report at Renub Research’s Viscosupplementation Market page.

About the Company

Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions. We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.

Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com

Categorized in:

Business,

Last Update: August 4, 2025

Tagged in: